GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viela Bio Inc (NAS:VIE) » Definitions » Net Change in Cash

Viela Bio (Viela Bio) Net Change in Cash : $-70.79 Mil (TTM As of Dec. 2020)


View and export this data going back to 2019. Start your Free Trial

What is Viela Bio Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Viela Bio's Net Change in Cash for the three months ended in Dec. 2020 was $18.42 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2020 was $-70.79 Mil.

Viela Bio Net Change in Cash Historical Data

The historical data trend for Viela Bio's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viela Bio Net Change in Cash Chart

Viela Bio Annual Data
Trend Dec18 Dec19 Dec20
Net Change in Cash
126.90 73.95 -70.79

Viela Bio Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.10 -37.28 -32.02 -19.90 18.42

Viela Bio Net Change in Cash Calculation

Viela Bio's Net Change in Cash for the fiscal year that ended in Dec. 2020 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-106.113+-124.25+159.577+0
=-70.79

Viela Bio's Net Change in Cash for the quarter that ended in Dec. 2020

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-8.459+26.66+0.215+0
=18.42

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-70.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viela Bio Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Viela Bio's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Viela Bio (Viela Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viela Bio Inc (NAS:VIE) » Definitions » Net Change in Cash
Comparable Companies
FOLD FGEN DCPH PTCT HALO ARNA AXSM QURE NVAX ARWR OCSE:NOVO B ASX:CSL VRTX REGN XKRX:207940 SGEN MRNA ALXN XKRX:068270 INCY
Traded in Other Exchanges
N/A
Address
One MedImmune Way, First Floor, Area Two, Gaithersburg, MD, USA, 20878
Website
https://www.vielabio.com
Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.
Executives
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Rachelle Suzanne Jacques director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Edward Hu director 10975 TORREY PINES ROAD, LA JOLLA CA 92037
Boyu Capital General Partner Iii, L.p. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital General Partner Iii, Ltd. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Group Holdings Ltd. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xyxy Holdings Ltd. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Investment Management Ltd 10 percent owner SUITE 1501, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boundless Meadow Ltd 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xiaomeng Tong director, 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Yanling Cao director, 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Fund Iii, L.p. 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KYL-1104
Boyu Capital Opportunities Master Fund 10 percent owner CAYMAN CORPORATE CENTRE 27 HOSPITAL ROAD, GEORGE TOWN CAYMAN ISLANDS E9 KY1-9008
Zhengbin Yao director, officer: Chief Executive Officer 10301 STELLA LINK ROAD, HOUSTON TX 77025
William Ragatz officer: VP, Head of Commercial C/O VIELA BIO, INC., ONE MEDIMMUNE WAY FIRST FLOOR, AREA TWO GAITHERSBURG MD 20878

Viela Bio (Viela Bio) Headlines

From GuruFocus

Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

By GlobeNewswire GlobeNewswire • 06-11-2020

Viela Bio to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on March 25, 2020

By Marketwired Marketwired • 03-18-2020

Viela Bio Reports Second Quarter 2020 Financial Results and Program Highlights

By Marketwired Marketwired • 08-13-2020

Viela Bio Announces Proposed Public Offering of Common Stock

By Marketwired Marketwired • 05-26-2020

Viela Bio to Webcast Third Quarter 2020 Financial Results and Program Highlights on November 10, 2020

By Marketwired Marketwired • 11-02-2020

Viela Bio Reports Third Quarter 2019 Financial Results and Business Highlights

By Marketwired Marketwired • 11-14-2019

Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus

By Marketwired Marketwired • 05-14-2020

Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

By Marketwired Marketwired • 06-12-2020

Shareholder Alert: Ademi LLP Investigates whether Viela Bio, Inc. has obtained a Fair Price in its transaction with Horizon

By PRNewswire PRNewswire • 02-01-2021

Viela Bio to Webcast First Quarter 2020 Financial Results and Program Highlights on May 13, 2020

By Marketwired Marketwired • 05-06-2020